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Abstract
Introduction: Data on the prevalence of nasopharyngeal carriage of S.pneumoniae in all age groups are important to help
predict the impact of introducing pneumococcal conjugate vaccines (PCV) into routine infant immunization, given the
important indirect effect of the vaccine. Yet most carriage studies are limited to children under five years of age. We here
explore the association between carriage prevalence and serotype distribution in children aged $5 years and in adults
compared to children.
Methods: We conducted a systematic review of studies providing carriage estimates across age groups in healthy
populations not previously exposed to PCV, using MEDLINE and Embase. We used Bayesian linear meta-regression models
to predict the overall carriage prevalence as well as the prevalence and distribution of vaccine and nonvaccine type (VT and
NVT) serotypes in older age groups as a function of that in ,5 y olds.
Results: Twenty-nine studies compromising of 20,391 individuals were included in the analysis. In all studies
nasopharyngeal carriage decreased with increasing age. We found a strong positive linear association between the
carriage prevalence in pre-school childen (,5 y) and both that in school aged children (5–17 y olds) and in adults. The
proportion of VT serotypes isolated from carriers was consistently lower in older age groups and on average about 73% that
of children ,5 y among 5–17 y olds and adults respectively. We provide a prediction model to infer the carriage prevalence
and serotype distribution in 5–17 y olds and adults as a function of that in children ,5 years of age.
Conclusion: Such predictions are helpful for assessing the potential population-wide effects of vaccination programmes,
e.g. via transmission models, and thus assist in the design of future pneumococcal conjugate vaccination strategies.
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Introduction
Colonization of the nasopharynx by Streptococcus pneumoniae is the
reservoir for S.pneumoniae transmission and a prerequisite for
pneumococcal disease [1]. Pneumococcal conjugate vaccines
(PCV) reduce nasopharyngeal carriage of serotypes included in
the vaccine by conferring capsular-specific immunity. Experience
from countries where conjugate vaccines have been introduced has
shown rapid and sustained carriage reduction of vaccine serotypes
(VT) following vaccination. Those trends have been observed not
only among vaccinated children but more widely across all age
groups through a strong herd immunity effect [2,3]. Despite
evidence of almost complete serotype replacement in many
settings, whereby non-vaccine serotypes (NVT) colonise the space
left vacant by vaccine type (VT) serotypes [4], pneumococcal
conjugate vaccination programmes have led to a substantial
reduction in severe disease due to the lower propensity of replacing
serotypes to cause disease [4,5].
Ten- and thirteen-valent pneumococcal conjugate vaccines
(PCV10 and PCV13) are now being introduced into the routine
immunization programmes of many developing countries (www.
jhsph.edu/ivac/vims.html), where their impact is expected to be
high, given the disproportionate burden of pneumococcal disease
in such settings [6].
Estimates of the potential impact of routinely introducing
pneumococcal conjugate vaccines (PCVs), however, crucially
depend on the nasopharyngeal carriage prevalence in the
population before the introduction of PCV, the distribution of
serotypes (VT and NVT) within the population, including among
older children, adults and the elderly, and the propensity of
replacing serotypes to cause disease across age groups.
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Most carriage surveys are limited to children under five years of
age, in whom the disease burden is high and for whom sample size
requirements for precision are reasonable given the high carriage
prevalence. As a result, nasopharyngeal carriage estimates in other
age groups are scarce. However, such estimates are important to
help predict the overall population impact of vaccination
programmes as well as the specific impact among unvaccinated
age groups. Routine infant PCV vaccination has been found to
also impact substantially on the elderly in whom the likelihood to
develop severe pneumococcal disease as a result of carriage is high
[7,8] and who present the highest overall burden of pneumocccal
associated disease in developed countries [9]. Hence this age group
has also played an important role in the cost effectiveness
considerations of pneumococcal conjugate vaccination [10,11].
With the proportion of population of .60 years old growing at its
fastest pace ever [12], the indirect effect of PCV vaccination
programmes may become increasingly important, including in
developing countries.
The overall aim of this study was to explore a possible
correlation between the prevalence and distribution of S.pneumoniae
serotypes carried in the nasopharynx of children ,5 y and that in
older children (5–17 y olds) and adults ($18 y olds), based on
nasopharyngeal carriage surveys, and further establish predictors
for carriage prevalence and serotype distribution in adults and
older children as a function of the carriage prevalence and
serotype distribution in the nasopharynx of children under five
years of age.
Methods
Search Strategy
We conducted a systematic review to identify articles reporting
nasopharyngeal carriage prevalence estimates for different age
strata. We used MEDLINE and Embase electronic databases to
retrieve articles published between the date of the earliest articles
compiled on MEDLINE (1946) or Embase (1947) and 23rd August
2013 (i.e. week 35), and used the following combination of search
terms: ‘(pneumonia OR pneumoniae OR pneumococcal OR
pneumococcus) AND (carriage OR colonization OR colonisation)’
in the title or the keywords or the abstract. No language restriction
was applied.
There is no registered protocol for this systematic review.
Our systematic review and meta-analysis was conducted in
accordance with the PRISMA checklist (http://www.prisma-
statement.org/statement.htm, see Checklist S1) and MOOSE
guidelines [13], which compile guidelines for the reporting of
meta-analysis of observational studies.
Eligibility Criteria
We included studies based on seven main eligibility criteria.
Articles were considered for inclusion if they provided (i)
pneumococcal nasopharyngeal carriage prevalence estimates (ii) in
a population not previously exposed to PCV, with (iii) nasopha-
ryngeal sampling and transport procedures as well as S.pneumoniae
culture based on WHO guidelines [14], (iv) where the study was
not restricted to specific serotypes or to S.pneumoniae with specific
patterns of antibiotic sensitivity. Studies were further considered
for inclusion if they provided carriage estimates in young children,
as well as in older age groups and (vi) in individuals not suffering
from any acute respiratory infection or any confirmed pneumo-
coccal disease, and (vii) were not based on particular at risk
population groups such as HIV positive individuals.
No design restriction was applied.
Data Extraction
The articles were screened and reviewed with inclusion criteria
appraised in the order described above. When primary data
published in a study were also used in subsequent studies, we
screened the latter too to find any data that may not have been
published in the original paper. For each study meeting the
aforementioned inclusion criteria we calculated the prevalence of
nasopharyngeal carriage by age group, as well as the prevalence of
VT and NVT by age group when provided, for PCV7 and/or
PCV10 and/or PCV13, depending on available data. In most
studies the group of NVT comprised of NVT serotypes as well as
non-typeable (NT) serotypes, while in a few studies estimates for
NT by age group were provided separately and were therefore not
included in the group of NVT serotypes.
In some studies estimates were provided by age or for smaller
age bands, and such estimates were therefore pooled to obtain
estimates for the main four age groups considered.
In longitudinal studies where multiple nasopharyngeal swabs
were taken for each individual, the number of individuals tested
positive was approximated by the age-specific average number of
positive swabs over the study period.
In a few studies the actual number of carriers had to be
estimated based on reported prevalence estimates and the number
of study participants in each age group.
More details on how the data were extracted from the different
studies can be found in File S1.
Analysis
We considered the following age groups: ,1 y (infants); ,5 y
(pre-school children including infants); 5–17 y (school aged
children) and $18 y (adults). Because age groups were not
standardised between studies, the category of ,5 y olds included
studies reporting estimates in ,4 y olds as well as studies reporting
estimates in ,6 y olds. The category of school-aged children
included any age group from between 4 to 6 years up to any age
between 10 years and 19 years, and we considered the prevalence
among adults to be that in individuals aged at least 15 years and
above.
We explored the association between the carriage prevalence
and VT or NVT distribution in older age groups and that in
young children using Bayesian linear meta-regression analysis.
The use of Bayesian over a frequentist approach was motivated by
the natural way in which each study’s contribution to the meta-
regression is weighted in a Bayesian approach, and also because
Bayesian linear regression is the recommended tool by the
Cochrane Collaboration to account for uncertainty around both
the outcome and the exposure variables in a meta-regression [15].
Age-dependent overall carriage prevalence and carriage
prediction. We obtained prediction intervals for the carriage
prevalence in adults and in 5–17 y olds as a function of that in
either ,5 y olds or ,1 y olds using a Bayesian linear meta-
regression model. For the i studies included in each analysis,
PAi~b0zb1  PCizei,
with PAi =prevalence in either adults or 5–17 y olds in study i,
Pci =prevalence in either ,5 y olds or ,1 y olds in study i and
ei = random error in study ei*N(0,s2).
The true prevalence PAi and Pci are unknown, however the
observed number of carriers in each study (XAi and XCi ) follows a
binomial distribution. Hence, based on these and on the sample
Predicting S.pneumoniae Carriage across Age Groups
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sizes (NAiand NCi) it follows that XAi , Binomial (PAi, NAi ) and,
Binomial (Pci, NCi ).
We provided prior distributions for the parameters of interest
b0, b1 and s and assigned uniform uninformative priors to b0 (unif
(21,1)) and b1 (unif (25,5)) and to s (unif (0,0.4)).
The posterior distributions were obtained through a Markov
Chain Monte Carlo (MCMC) Gibbs sampling algorithm, with
100,000 iterations of 2 chains running in parallel, after a burn-in of
5,000 iterations. We retained one in five iterations in the posterior
sample to limit autocorrelation. Convergence of the chains was
examined visually. We obtained the 95% posterior credible
intervals (CrI) for the model regression line as well as the posterior
credible intervals for the prediction of individual studies by
including the prediction error (which we will refer to as the
‘‘prediction interval’’ in the results section).
We further explored the possible association of socio-demo-
graphic and geographic characteristics of the populations studied
through Bayesian multivariable meta-regression. The explanatory
variables considered for meta-regression included the proportion
of children ,5 y of age and the % ,15 y of age in the country or
area in which the study took place based on figures obtained from
UN Population data (http://esa.un.org/wpp/), categories of
national income level in the country or area in which the study
took place, based on estimates from the World Bank (http://data.
worldbank.org/), and broad geographical areas or continents in
which studies took place. Variables were added one after another
in the model and were retained if the 95% posterior probability
interval for their coefficient excluded 0.
Age-dependent distribution of VT serotypes. We then
explored (i) the distribution of the group of VT serotypes among
carried serotypes in children ,5 y and in older age groups, and
the association between such distributions, as well as (ii) the
relationship between the prevalence of VT carriage and NVT
carriage in adults and in 5–17 y olds compared to children ,5
years of age.
For each study providing serotype-specific information we
calculated (i) the proportion of VT serotypes (for PCV7 or PCV10
or PCV13) among carriers in children and older age group, and
their 95% confidence interval (CI) and (ii) the carriage prevalence
of such groups of serotypes, by age category and 95% CI.
We further explored the relationship between (i) the proportion
of VT carriers and (ii) the VT and NVT carriage prevalence across
age groups using Bayesian linear meta-regression. We used the
same uniform priors for b0, b1 and s than in the analysis of overall
carriage prevalence, as well as the same analytical strategy to
obtain posterior estimates.
The code used for the Bayesian linear meta-regression can be
found in File S2 and is fully annotated. In addition, File S2 also
provides an opportunity for readers to obtain posterior distribu-
tions of the carriage prevalence in 5–17 y olds and adults based on
study-specific estimates of nasopharyngeal carriage in ,5 y olds,
making it possible to use this as a carriage prediction tool based on
specific data of carriage in ,5 y olds.
Analyses were performed using R software and the JAGS
package in R (http://mcmc-jags.sourceforge.net/).
Results
A total of 8,886 citations were found, which amounted to 4,648
citations after duplicates were excluded. Of those, 376 original
studies provided pre-PCV nasopharyngeal carriage estimates in
healthy individuals. A flowchart of the number of studies screened
and reasons for exclusion is displayed in Figure 1.
A total of 29 studies were included in the meta-analysis,
comprising a total of 20,391 individuals, including 7931 children
,5 y, 3936 school aged children and 8524 adults.
Age Dependent Prevalence of Nasopharyngeal Carriage
Seven studies were conducted in Africa, 6 in Asia, 6 in the
Middle-East, 5 in Europe, 2 in the North America (Alaska, USA)
and 3 in South America. Table 1 displays the main characteristics
of the studies included in the final analysis, including details about
how individuals were selected in each age group, as well as the
estimates of carriage prevalence by age group.
We found a strong positive correlation between carriage
prevalence in younger age groups and that in older age groups.
Figure 2 displays a scatter plot of the study specific estimates for
the prevalence in adults and in 5–17 y olds as a function of that in
either ,5 y olds or ,1 y olds. The figure also displays the fitted
regression line from the Bayesian linear meta-regression model,
including the median posterior estimate, the 95% credible interval
around the median, as well as the 95% prediction intervals for all
four analyses. The model coefficients of all four models can be
found in Table 2.
We explored whether the results from the regression model
were confounded by the socio-demographic and geographic
characteristics of the study population, but found no evidence
that the proportion of children, the national income level or the
geographic region of the included studies were associated with the
outcome in any of the models considered. In all analyses and for all
models considered the values of b1 coefficients were unaffected
and the coefficients of the variable explored were centred around
zero.
We also explored whether prediction estimates for the adult
population differed with studies (n = 11) where a random
community or hospital sample of adults was taken compared to
studies (n = 8) based on convenience sampling of parents,
guardians or day care centre staff looking after children included
(see Table 1 for further details). We found no difference in the
prediction estimates obtained in subgroup analyses. Figure S1
shows the plot for those analyses.
Specific estimates in older adults were provided in two studies
included in the analysis, one in Israel with data in .65 y olds [16]
and another in Kenya with data in .50 y olds [17]. Based on the
reported data there was no evidence that the carriage prevalence
among older adults differed substantially from that in younger
adults (Israel: 3.7% in 18–65 y vs. 4.6% in .65 y, p = 0.573 and
Kenya: 5.6% in 20–49 y olds vs. 4.6% in $50 y olds, p = 0.719).
Age-dependent Prevalence of VT Carriage and
Distribution of VT Serotypes
A total of eleven studies provided estimates of the distribution of
VT and NVT serotypes in young children and in older children
and/or adults. In all studies included serotyping was performed
using standard methods such as latex agglutination and capsular
swelling (Quellung reaction).
Estimates from a study in Israel [16] were based on outpatients,
including a proportion of patients with upper respiratory tract
infections (URTI), as serotype specific estimates could not be
obtained for the healthy study participants only. Data on the
serotype distribution among participants of two studies [18,19]
were extracted from subsequent manuscripts [20,21] as the
information was unavailable in the original articles. Two studies
included in the analysis only provided estimates in ,2 y olds
rather than ,5 y olds. However, as meta-regression coefficients,
obtained with and without the inclusion of such studies, were
similar we included both studies in the final analysis.
Predicting S.pneumoniae Carriage across Age Groups
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Figure 1. Flow chart of the study selection process.
doi:10.1371/journal.pone.0086136.g001
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Table 3 provides details of the studies included in the analysis.
The proportion of VT serotypes isolated from positive swabs was
consistently lower in older age groups compared to children under
five, and that of NVT serotypes consistently higher. This finding
was consistent across studies.
We found a positive linear relationship between the proportion
of VT serotypes isolated from carriers in children under five and
that in 5–17 y olds or in adults (Figure 3). The intercept was
centred around zero in both models, and the slope of the
coefficient was 0.73 (Credible intervals (CrI) 0.10–1.37) in 5–17 y
old and 0.73 (95%CrI 0.06; 1.32) in adult carriers compared to the
proportion of VT serotypes in children ,5 y. Further details on
the model coefficients are provided in Table 3.
We then analysed the relationship between VT and NVT
carriage prevalence in ,5 y olds and 5–17 y olds or adults. As for
the overall carriage prevalence, there was good evidence of a
linear trend, with the prevalence of both VT and NVT in older
age groups increasing with increasing VT and NVT prevalence in
,5 s (Figures 4 and 5). However, given the shift in VT/NVT
distribution in older age groups, the prevalence of VT serotypes in
5–17 y olds and adults compared to that in children under five was
comparatively lower than that of NVT serotypes (Table 2).
We performed subgroup analyses for VT serotypes included in
PCV7 and VT serotypes included in PCV13, and found no
difference in the coefficient obtained. Hence for studies reporting
estimates for both PCV7 and PCV13 we included in the final
analysis estimates with VT serotypes included in the higher
valency vaccine.
Discussion
In this systematic review and meta-analysis the prevalence of
Streptococcus pneumoniae carriage in the nasopharynx of children aged
under five was strongly correlated with the prevalence of
nasopharyngeal carriage in older age groups. Furthermore, we
found that the proportion of carriage attributed to vaccine
serotypes was consistently decreasing with age. Our study provides
a tool to help make informed predictions, however with some
uncertainty, on the carriage prevalence and serotype distribution
in older children and adults solely based on data in children ,5 y
of age, which are more widely available.
The results of this study showed that despite the important
geographic heterogeneity in carriage prevalence, there is a stable
linear relationship between the carriage prevalence in young
Figure 2. Overall carriage prevalence in older age groups against ,5 y olds: scatter plot and fitted model. Each circle corresponds to
one study, with the circle size proportional to the study size (i.e. number of individuals contributing to the x and y axis estimates). The lines
correspond to the fitted Bayesian linear meta-regression model. The dashed black line shows the median posterior estimate and the grey shaded area
the 95% credible interval around the median. The red dotted lines represent the 95% prediction interval.
doi:10.1371/journal.pone.0086136.g002
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children and that in older children and adults. Such relationship
also held for VT and NVT separately, although with different
magnitude given the shift in serotype distribution in older age
groups, with proportionally more NVT and less VT carriers.
While a proportional decrease of carriage prevalence by age, as
described by a linear correlation with an intercept centred around
zero, did not describe the data well in most instances, the addition
of a flexible intercept allowed for a good description of the age-
dependent carriage association.
Although the decrease in carriage prevalence through childhood
is a well established fact, the between age group correlation in
prevalence estimates has – to the best of our knowledge – not been
previously described. These results are important to help improve
our understanding of carriage and disease dynamics in the
population, assess the potential population-wide effects of vacci-
nation programmes and help design appropriate vaccination
strategies. Given the high carriage prevalence rates found in
children in many developing countries the indirect impact of
routine infant PCV immunization on older children and adult
populations in such countries is likely to be high, as we find that
carriage rates in those age groups are likely to high as well.
The general decrease in prevalence with increasing age can be
caused by numerous factors, including the decrease in the duration
of carriage with age [22,23], the reduction in the number of
effective contacts as age increases, as well as the general
maturation of the immune system [24].
Immunity induced by S.pneumoniae carriage is complex and still
poorly understood [25]. Although carriage acquisition leads to the
development of capsular antibodies, evidence suggests that such
antibodies may not be the primary driver of the decrease in
duration and prevalence of carriage with age [26]. Mouse models
have shown that the development of immunity against coloniza-
tion in mice depends on CD4+ T cells rather than serotype-
specific antibodies as such, in particular T-cells secreting IL-17A
(TH17 cells) [27], and there is evidence that TH17 cells play a role
in immunity against carriage in humans too [28].
Yet despite the uncertainty around the exact immune mecha-
nisms, or the contribution of each of those towards acquired long
term immunity, epidemiological evidence suggest that serotype-
specific immunity against colonization is induced by acquisition of
some serotypes such as 6A, 14 and 23F, which are included in
PCV formulations and are some of the most prevalent serotypes in
early childhood [24]. Hence the progressive acquisition of
immunity against VT serotypes may also explain the shift in
serotype distribution towards proportionally more NVT as age
increases, as immunity against VT serotypes acquired in early
childhood may reduce the likelihood of acquiring such serotypes
later in life [29].
There are several direct applications of our study results.
Given that most studies are confined to children ,5 y of age
only, the results of this study are particularly useful in the context
of the progressive introduction of PCV10 or PCV13 in many
developing countries, in order to help estimate and appraise the
possible impact of the vaccine across age groups. For example,
nasopharyngeal carriage estimates are central to dynamic models
of disease transmission [30,31], which can be used to model pre-
vaccination dynamics and estimate post vaccination trends. With
the results of this study, such models could be implemented in
settings in which pre-vaccination data are only available in young
children.
The quantification of the magnitude of change in carriage
prevalence between children ,5 y and older age groups is also
helpful in the sample size calculations of nasopharyngeal carriage
surveys across age groups.
While the specific associations found between VT and NVT
carriage prevalence across age groups may not hold for new higher
valency vaccines under development, the estimates of overall
carriage prevalence across age groups may help evaluate the
possible population wide impacts on carriage of new protein-based
or killed whole cell serotype-independent candidate vaccines [28].
As a practical application of the presented work we predicted
the carriage prevalence in older children and adults based on
carriage in under 5 year olds in an aboriginal population in the
Northern Territory in Australia [33]. This study was not included
in the analysis as it was conducted after the introduction of PCV.
However, no change in overall carriage prevalence was observed
in the three first years post PCV in this population. Hence we
assumed that under a scenario of full serotype replacement overall
carriage estimates by age group after PCV implementation would
match those from the pre-PCV period. Using such data, we
estimated the prevalence in 5–17 y olds and adults to be 58.1%
(95% prediction 38.7–77.4%) and 32.4% (95%prediction 14.8–
48.8%) respectively, based on data in children under five. This
closely matches the study estimates, with the prevalence in 5–17 y
olds estimated at 60.9% (95%CI 54.5% - 67.0%) and that in adults
estimated at 26.0% (95%CI 22.3–29.9%).
Our study also suffers a range of limitations.
We did not restrict our analysis to any particular design and
sampling strategy, and recruitment bias is likely to have occurred,
in particular for studies based on convenience rather than random
sampling, which was seen frequently for the adult age group.
However, our subgroup analyses showed no difference in the
prediction estimates of the overall carriage prevalence obtained
with studies based on random samples of adults compared to
studies based on a convenient sample of relatives or carers of the
children included.
By restricting the analysis to broad age groups, we overlooked
changes in carriage prevalence within each of those groups. In
particular, the prevalence of carriage in the 5–17 y olds is known
to decline between the ages of 5 and 17 years. This may also
account for some of the heterogeneity seen between studies, as in
Table 2. Model coefficients for each of the Bayesian linear
meta-regression models used.
Model Intercept (b0) Slope (b1)
median (95% CrI) median (95% CrI)
Overall carriage prevalence
Adults vs. ,5 y 20.18 (20.31; 20.05) 0.57 (0.35;0.80)
Adults vs. ,1 y 20.36 (20.49; 20.15) 0.83 (0.52; 1.03)
5–17 y vs. ,5 y 20.00 (20.10; 0.10) 0.68 (0.48; 0.86)
5–17 y vs. ,1 y 20.38 (20.49; 20.09) 1.22 (0.79; 1.40)
VT carriage prevalence
Adults vs. ,5 y 20.06 (20.17; 0.05) 0.34 (0.05; 0.62)
5–17 y vs. ,5 y 20.10 (20.41; 0.20) 0.73 (0.00; 1.43)
NVT carriage prevalence
Adults vs. ,5 y 20.10 (20.30; 0.09) 0.76 (0.11; 1.46)
5–17 y vs. ,5 y 20.04 (20.21; 0.14) 1.27 (0.63; 1.89)
VT proportion among carriers
Adults vs. ,5 y 20.07 (20.41; 0.33) 0.73 (0.06;1.32)
5–17 y vs. ,5 y 20.03 (20.41; 0.33) 0.73 (0.10; 1.37)
doi:10.1371/journal.pone.0086136.t002
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many studies the age representation of the 5–17 y olds in the study
sample may not have matched that of the general population.
Between-study heterogeneity may also have resulted from
individual confounding factors associated with carriage preva-
lence, which we were unable to account for, such as malnutrition,
antibiotic use or smoking [32,33].
Further, although standard WHO laboratory procedures [14]
were reported in all studies, differences in swabbing techniques,
number of colonies plated, processing of specimens and culture
may also account for some of the differences seen. There was
however good homogeneity in the serotyping methods used in all
studies included.
We could not specifically estimate the carriage prevalence
among the elderly as a function of that in young children, given
the paucity of data. Having specific estimates in elderly would be
important however, given the particularly high burden of
pneumococcal disease in that age group and the potential indirect
impact of routine PCV on carriage in them. While no significant
difference in carriage prevalence between younger and older
adults was reported in two studies that provided specific data on
older adults or elderly [16,17], more data are required to enable
specific estimates to be made for that age group.
Finally, model estimates of VT and NVT prevalence in older
age groups as a function of that in young children were prone to
more uncertainty than in the models based on overall carriage
prevalence, given that fewer studies reported specific carriage data
by groups of serotypes. In addition, those models were based on
prevalence estimates which were mostly confined to the lower
prevalence levels, resulting in substantial model uncertainty for
high prevalence estimates. Further carriage studies will help
improve the precision around such estimates, and the analysis can
easily be updated with the model code provided in the Supporting
Information.
Conclusions
Information on patterns of nasopharyngeal colonisation in
individuals not directly targeted by pneumococcal conjugate
vaccination is scarce but plays an important role in the
consideration of the indirect impact of PCVs. We here present
evidence that a non-trivial stable relationship between child and
both adolescent and adult carriage rates holds. Furthermore we
show that a similar relationship for the proportion of vaccine type
and non-vaccine type carriage is present. We exploit these and
Figure 3. VT proportion in carried serotypes among ,5 y and older ages: scatter plot and fitted model. Each circle corresponds to one
study, with the circle size proportional to the study size (i.e. number of individuals contributing to the x and y axis estimates). The lines correspond to
the fitted Bayesian linear meta-regression model. The dashed black line shows the median posterior estimate and the grey shaded area the 95%
credible interval around the median. The red dotted lines represent the 95% prediction interval.
doi:10.1371/journal.pone.0086136.g003
Figure 4. VT and NVT prevalence in 5–17 y olds against ,5 y olds: scatter plot and fitted model. Each circle corresponds to one study,
with the circle size proportional to the study size (i.e. number of individuals contributing to the x and y axis estimates). The lines correspond to the
fitted Bayesian linear meta-regression model. The dashed black line shows the median posterior estimate and the grey shaded area the 95% credible
interval around the median. The red dotted lines represent the 95% prediction interval.
doi:10.1371/journal.pone.0086136.g004
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provide a tool to make an informed prediction of carriage rates in
adolescents and adults based on childhood carriage rates only,
including the associated uncertainty. Further carriage studies on
broad age ranges will allow narrowing of the prediction intervals.
If designed accordingly these could also provide the basis for
childhood carriage informed estimates of carriage in the elderly
population which is particularly affected by pneumococcal disease.
Supporting Information
Figure S1 Overall carriage prevalence in adults against
,5 y olds, by sampling characteristics of the adult
population: scatter plot and fitted model. Each circle
corresponds to one study, with the circle size proportional to the
study size (i.e. number of individuals contributing to the x and y
axis estimates). The lines correspond to the fitted Bayesian linear
meta-regression model. The dashed black line shows the median
posterior estimate and the grey shaded area the 95% credible
interval around the median. The red dotted lines represent the
95% prediction interval.
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